Prostate Cancer

Around 32,000 men in the UK are diagnosed with prostate cancer each year. It differs from most other cancers in the body, in that small areas of cancer within the prostate are very common and may not grow or cause any problems for many years. This new edition of the book has been heavily updated and includes information on new treatments available.

Professor Malcolm Mason is an Oncologist with a special interest in prostate cancer. He has been closely involved in clinical trials in prostate cancer for the Medical Research Council for over 18 years, and he has had a research programme in Cardiff University into this disease since 1997. He qualified in London at St Bartholomew's Hospital, and trained in Oncology at the Royal Marsden Hospital, London. He moved to Cardiff in 1992. He is also past-Chairman of the British Prostate Group.
In 2009, Professor Mason was appointed the Chairman of the National cancer Research Institute's Prostate Cancer Clinical Studies Group, the main UK group responsible for developing and overseeing clinical trials in prostate cancer in the UK.
Mr Leslie Moffat trained in Edinburgh and Glasgow. He published the largest study of LHRH analogues Chairman of Scottish Urological Cancer Audit, the largest of its kind in the world.

- 1: Introduction
- 2: How do doctors measure the severity and extent of a prostate cancer?
- 3: Risks and benefits of screening and radical treatment - a guide
- 4: Treatment and management options
- 5: Screening
- 6: Hormone therapy
- 7: Locally Advanced Disease
- 8: Advanced Disease
- 9: Alternative treatments
- 10: Chemo prevention and vitamins
- 11: Clinical Trials
- 12: Prostate cancer and sex
- 13: Questions and answers
- Glossary
- Sources of information